Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has announced a strategic move to acquire the global portfolio of Nicotinell and other brands in the Nicotine Replacement Therapy (NRT) category from Haleon plc, excluding the United States. The acquisition, involving a definitive agreement for the purchase of shares of Northstar Switzerland SARL, is aimed at bolstering Dr. Reddy’s presence in the global consumer healthcare OTC business, leveraging a portfolio that earned approximately GBP 217 million in revenue in CY 2023.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
